Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Struble K, Chan-Tack K, Qi K, Naeger LK, et al. Benefit-Risk Assessment for Sofosbuvir/Velpatasvir/Voxilaprevir Based on Patient Population and HCV genotype: FDA's Evaluation. Hepatology 2017 Oct 23. doi: 10.1002/hep.29601.
PMID: 29059462


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016